Vesta Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-07-2024
- Paid Up Capital ₹ 1.00 M
as on 18-07-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 29.71%
(FY 2022)
- Profit -130.86%
(FY 2022)
- Ebitda -314.41%
(FY 2022)
- Net Worth -2.53%
(FY 2022)
- Total Assets -7.10%
(FY 2022)
About Vesta Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Deepti Batra and Sameer Sethi serve as directors at the Company.
- CIN/LLPIN
U24232DL2010PTC211826
- Company No.
211826
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2010
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Vesta Biotech Private Limited offer?
Vesta Biotech Private Limited offers a wide range of products and services, including Antifungal Cream, Ointment & Powder, Clobetasol Propionate Cream, Vitamin Tablets & Capsules, Cholecalciferol Granules, Antibacterial Drugs, Ofloxacin Ornidazole Tablets, Clindamycin & Nicotinamide Gel, Pharmaceutical Medicine, Lycopene, Antacid Drugs.
Who are the key members and board of directors at Vesta Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepti Batra  | Director | 27-Mar-2015 | Current |
| Sameer Sethi | Director | 25-Mar-2023 | Current |
Financial of Vesta Biotech.
Vesta Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 29.71% increase. The company also saw a substantial fall in profitability, with a 130.86% decrease in profit. The company's net worth dipped by a decrease of 2.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vesta Biotech?
In 2022, Vesta Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Best Healthsciences Private LimitedActive 12 years 8 monthsDeepti Batra and Sameer Sethi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vesta Biotech?
Vesta Biotech has a workforce of 6 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vesta Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vesta Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
